158 related articles for article (PubMed ID: 8763854)
1. Antivascular approaches to solid tumour therapy: evaluation of tubulin binding agents.
Chaplin DJ; Pettit GR; Parkins CS; Hill SA
Br J Cancer Suppl; 1996 Jul; 27():S86-8. PubMed ID: 8763854
[TBL] [Abstract][Full Text] [Related]
2. Anti-vascular approaches to solid tumour therapy: evaluation of combretastatin A4 phosphate.
Chaplin DJ; Pettit GR; Hill SA
Anticancer Res; 1999; 19(1A):189-95. PubMed ID: 10226542
[TBL] [Abstract][Full Text] [Related]
3. Sustained intracellular retention of dolastatin 10 causes its potent antimitotic activity.
Verdier-Pinard P; Kepler JA; Pettit GR; Hamel E
Mol Pharmacol; 2000 Jan; 57(1):180-7. PubMed ID: 10617693
[TBL] [Abstract][Full Text] [Related]
4. The spongistatins, potently cytotoxic inhibitors of tubulin polymerization, bind in a distinct region of the vinca domain.
Bai R; Taylor GF; Cichacz ZA; Herald CL; Kepler JA; Pettit GR; Hamel E
Biochemistry; 1995 Aug; 34(30):9714-21. PubMed ID: 7626642
[TBL] [Abstract][Full Text] [Related]
5. Enhancement of the antitumor effect of flavone acetic acid by the bioreductive cytotoxic drug SR 4233 in a murine carcinoma.
Sun JR; Brown JM
Cancer Res; 1989 Oct; 49(20):5664-70. PubMed ID: 2790784
[TBL] [Abstract][Full Text] [Related]
6. Combretastatin dinitrogen-substituted stilbene analogues as tubulin-binding and vascular-disrupting agents.
Siles R; Ackley JF; Hadimani MB; Hall JJ; Mugabe BE; Guddneppanavar R; Monk KA; Chapuis JC; Pettit GR; Chaplin DJ; Edvardsen K; Trawick ML; Garner CM; Pinney KG
J Nat Prod; 2008 Mar; 71(3):313-20. PubMed ID: 18303849
[TBL] [Abstract][Full Text] [Related]
7. Anti-vascular approaches to solid tumour therapy: evaluation of vinblastine and flavone acetic acid.
Hill SA; Sampson LE; Chaplin DJ
Int J Cancer; 1995 Sep; 63(1):119-23. PubMed ID: 7558438
[TBL] [Abstract][Full Text] [Related]
8. Vascular collapse after flavone acetic acid: a possible mechanism of its anti-tumour action.
Hill S; Williams KB; Denekamp J
Eur J Cancer Clin Oncol; 1989 Oct; 25(10):1419-24. PubMed ID: 2591434
[TBL] [Abstract][Full Text] [Related]
9. Dolastatin 15, a potent antimitotic depsipeptide derived from Dolabella auricularia. Interaction with tubulin and effects of cellular microtubules.
Bai R; Friedman SJ; Pettit GR; Hamel E
Biochem Pharmacol; 1992 Jun; 43(12):2637-45. PubMed ID: 1632820
[TBL] [Abstract][Full Text] [Related]
10. Structural and biochemical comparison of the anti-mitotic agents colchicine, combretastatin A4 and amphethinile.
McGown AT; Fox BW
Anticancer Drug Des; 1989 Mar; 3(4):249-54. PubMed ID: 2930627
[TBL] [Abstract][Full Text] [Related]
11. Differential effects of active isomers, segments, and analogs of dolastatin 10 on ligand interactions with tubulin. Correlation with cytotoxicity.
Bai R; Roach MC; Jayaram SK; Barkoczy J; Pettit GR; Ludueña RF; Hamel E
Biochem Pharmacol; 1993 Apr; 45(7):1503-15. PubMed ID: 8471072
[TBL] [Abstract][Full Text] [Related]
12. Increased plasma serotonin following treatment with flavone-8-acetic acid, 5,6-dimethylxanthenone-4-acetic acid, vinblastine, and colchicine: relation to vascular effects.
Baguley BC; Zhuang L; Kestell P
Oncol Res; 1997; 9(2):55-60. PubMed ID: 9167186
[TBL] [Abstract][Full Text] [Related]
13. Dolastatin 10, a powerful cytostatic peptide derived from a marine animal. Inhibition of tubulin polymerization mediated through the vinca alkaloid binding domain.
Bai R; Pettit GR; Hamel E
Biochem Pharmacol; 1990 Jun; 39(12):1941-9. PubMed ID: 2353935
[TBL] [Abstract][Full Text] [Related]
14. Spongistatin 1, a highly cytotoxic, sponge-derived, marine natural product that inhibits mitosis, microtubule assembly, and the binding of vinblastine to tubulin.
Bai R; Cichacz ZA; Herald CL; Pettit GR; Hamel E
Mol Pharmacol; 1993 Oct; 44(4):757-66. PubMed ID: 8232226
[TBL] [Abstract][Full Text] [Related]
15. Combining bioreductive drugs (SR 4233 or SN 23862) with the vasoactive agents flavone acetic acid or 5,6-dimethylxanthenone acetic acid.
Cliffe S; Taylor ML; Rutland M; Baguley BC; Hill RP; Wilson WR
Int J Radiat Oncol Biol Phys; 1994 May; 29(2):373-7. PubMed ID: 8195036
[TBL] [Abstract][Full Text] [Related]
16. Dolastatin 15 binds in the vinca domain of tubulin as demonstrated by Hummel-Dreyer chromatography.
Cruz-Monserrate Z; Mullaney JT; Harran PG; Pettit GR; Hamel E
Eur J Biochem; 2003 Sep; 270(18):3822-8. PubMed ID: 12950266
[TBL] [Abstract][Full Text] [Related]
17. Design, synthesis, and biological evaluation of combretastatin nitrogen-containing derivatives as inhibitors of tubulin assembly and vascular disrupting agents.
Monk KA; Siles R; Hadimani MB; Mugabe BE; Ackley JF; Studerus SW; Edvardsen K; Trawick ML; Garner CM; Rhodes MR; Pettit GR; Pinney KG
Bioorg Med Chem; 2006 May; 14(9):3231-44. PubMed ID: 16442292
[TBL] [Abstract][Full Text] [Related]
18. Interaction of dolastatin 10 with bovine brain tubulin.
Ludueña RF; Roach MC; Prasad V; Pettit GR
Biochem Pharmacol; 1992 Feb; 43(3):539-43. PubMed ID: 1540211
[TBL] [Abstract][Full Text] [Related]
19. Interactions of the sponge-derived antimitotic tripeptide hemiasterlin with tubulin: comparison with dolastatin 10 and cryptophycin 1.
Bai R; Durso NA; Sackett DL; Hamel E
Biochemistry; 1999 Oct; 38(43):14302-10. PubMed ID: 10572005
[TBL] [Abstract][Full Text] [Related]
20. Exploring vascular dysfunction caused by tirapazamine.
Huxham LA; Kyle AH; Baker JH; McNicol KL; Minchinton AI
Microvasc Res; 2008 Mar; 75(2):247-55. PubMed ID: 18023823
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
